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Background: Thiazolidindiones (TZDs) have been shown to increase incidence of peripheral edema and congestive heart failure by their water 
and sodium retention effects. The aim of this study was to investigate impact of pioglitazone on the left ventricular filling pressure in patients with 
ischemic heart disease and type 2 diabetes who underwent percutaneous coronary intervention (PCI).
Methods: A total of 51 patients (23 patients in the pioglitazone group and 28 patients in the control group) from the Prevention Of in-stent 
neointimal Proliferation by Pioglitazone Study (POPPS)were enrolled in this sub-study. Echocardiographic examinations including tissue Doppler 
imaging were performed at baseline and at repeated 6 months after PCI. Serial changes in systolic and diastolic indices were compared. E/e’ was 
used as an index of the left ventricular filling pressure.
Results: Baseline echocardiographic indices were similar between the pioglitazone group and control group. During 6 months follow-up. E/E’ 
decreased significantly in the control group (15.0±6.4 to 13.3±6.5, p=0.046), but not in the pioglitazone group (12.8±4.2 to. 14.2±5.3, p=0.19). 
Although echocardiographic indices at 6 months were also similar between the 2 groups, serial changes in E/e’ (delta E/e’) was significantly greater 
in the pioglitazone group than in the control group (1.4±5.0 vs. -1.7±4.4, p=0.02). On the other hand, serial changes in left ventricular systolic 
(delta EF, delta LV wall motion score index) and diastolic indices (delta E/A, delta deceleration time of E, delta e’) were similar between the 2 
groups. Incidence of peripheral edema and heart failure did not differ between the 2 groups.
Conclusion: Pioglitazone administration may affect left ventricular filling pressure without worsening left ventricular systolic and diastolic indices 
in patients with symptomatic ischemic heart disease who underwent PCI.
